HC Wainwright & Co. Maintains Buy on Foghorn Therapeutics, Lowers Price Target to $5
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Buy and lowers the price target from $13 to $5.